CrossrefInfokarte
Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care
The American Journal of Managed Care · 2025-11-18 · 31 (11) · e322
DOI: 10.37765/ajmc.2025.89822 ↗Abstract
Kein Abstract verfügbar.
EUVIMED